Keywords: case–control study; diabetes; hepatocellular carcinoma; metabolic syndrome; obesity

Metabolic syndrome and hepatocellular carcinoma risk

F Turati^{1,2}, R Talamini³, C Pelucchi¹, J Polesel³, S Franceschi⁴, A Crispo⁵, F Izzo⁶, C La Vecchia^{*1,2}, P Boffetta^{7,8} and M Montella⁵

¹Istituto di Ricerche Farmacologiche 'Mario Negri', via G. La Masa 19, 20156 Milan, Italy; ²Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, via Vanzetti 5, 20133 Milan, Italy; ³SOC di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Via F. Gallini 2, 33081 Aviano (PN), Italy; ⁴International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France; ⁵Dipartimento di Epidemiologia, 'Fondazione G. Pascale', Istituto Nazionale Tumori, via M. Semmola, 80131 Naples, Italy; ⁶Divisione di Chirurgia Istituto Nazionale dei Tumori Fondazione 'G. Pascale', via M. Semmola, 80131 Naples, Italy; ⁷International Prevention Research Institute, Cours Lafayette 95, 69006 Lyon France and ⁸Institute for Transitional Epidemiology and Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box No. 1057, New York, NY 10029, USA

Background: Hepatocellular carcinoma (HCC) has been associated to diabetes and obesity, but a possible association with the metabolic syndrome (MetS) and its potential interaction with hepatitis is open to discussion.

Methods: We analysed data from an Italian case–control study, including 185 HCC cases and 404 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed from unconditional logistic regression models.

Results: Among the MetS components, diabetes and obesity (i.e. body mass index (BMI) $\geq 30 \text{ kg m}^{-2}$) were positively associated to HCC risk, with ORs of 4.33 (95% CI, 1.89–9.86) and 1.97 (95% CI, 1.03–3.79), respectively. The ORs for the MetS were 4.06 (95% CI, 1.33–12.38) defining obesity as BMI ≥ 25 , and 1.92 (95% CI, 0.38–9.76) defining it as BMI ≥ 30 . The risk increased with the number of MetS components, up to an almost four-fold excess risk among subjects with ≥ 2 MetS factors. Among subjects without chronic infection with hepatitis B and/or C, the OR for those with ≥ 2 MetS components was over six-fold elevated. There was no consistent association in subjects with serological evidence of hepatitis B and/or C infection.

Conclusion: This study found that the risk of HCC increases with the number of MetS components in subjects not chronically infected with hepatitis viruses.

Worldwide, liver cancer is the third most common cause of cancer death among men and the sixth one among women (Llovet *et al*, 2003; London and McGlynn, 2006). Hepatocellular carcinoma (HCC) is the most frequent histologic type of primary liver cancer (Stuver and Trichopoulos, 2008), accounting for up to 85% of cases. The predominant role of chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in the aetiology of HCC is well documented (Llovet *et al*, 2003; London and McGlynn, 2006; Mueller *et al*, 2006). Advanced age, male gender, heavy

alcohol drinking, tobacco smoking and cirrhosis are other important recognised HCC risk factors (Llovet *et al*, 2003; London & McGlynn, 2006; Mueller *et al*, 2006).

The metabolic syndrome (MetS) is a series of metabolically related conditions, consistently associated with an increased risk of cardiovascular diseases (Alberti *et al*, 2006, 2009). Since the late 90s, several definitions have been developed for MetS; these were based on glucose intolerance–hyperglycemia–diabetes, obesity, hypertension and dyslipidemia, but differed in the details and

*Correspondence: Professor C La Vecchia;
E-mail: carlo.lavecchia@marionegri.it

Received 18 April 2012; revised 8 October 2012; accepted 11 October 2012; published online 20 November 2012

© 2013 Cancer Research UK. All rights reserved 0007–0920/13

criteria (Alberti and Zimmet, 1998; Third Report of the NCEP Expert Panel, 2002; Alberti *et al*, 2005; Grundy *et al*, 2005). MetS components reflect overnutrition and sedentary lifestyle resulting in excess adiposity. A consensus statement by the major scientific associations in the field of metabolic disorders proposed common criteria for the clinical diagnosis of the MetS ('joint interim statement'), that is, the presence of at least three of the following conditions: elevated waist circumference (for abdominal obesity), elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol, elevated blood pressure, and elevated fasting glucose (Alberti *et al*, 2009). Several epidemiological studies reported positive associations between obesity and diabetes and the risk of primary liver cancer, whereas data on the association with other MetS components are scanty (Adami *et al*, 1996; Wideroff *et al*, 1997; Lagiou *et al*, 2000; El-Serag *et al*, 2004; Yuan *et al*, 2004; Lai *et al*, 2006; Larsson and Wolk, 2007; Polesel *et al*, 2009). A limited number of studies analysed the relationship between MetS and liver cancer, suggesting a positive association (Russo *et al*, 2008; Inoue *et al*, 2009; Borena *et al*, 2011; Welzel *et al*, 2011), but quantification and particularly the possible relation between MetS and HBV/HCV remain open to discussion.

We provided further results on this issue using data from a multicentric case-control study conducted in Italy. In addition, we explored the association between MetS and HCC risk among subgroups of hepatitis-free and affected subjects.

MATERIALS AND METHODS

Between 1999 and 2002, a case-control study on HCC was carried out in the province of Pordenone (North-eastern Italy) and in the city of Naples (southern Italy) (Talamini *et al*, 2004; Franceschi *et al*, 2006; Montella *et al*, 2011b). Cases were subjects younger than 85 years with incident HCC, admitted to teaching and general hospitals in Pordenone and Naples. Out of the 261 HCC cases satisfying the inclusion criteria, 3 refused the participation, 29 did not supply blood samples, and 44 did not have anthropometric measures at cancer diagnosis. For the remaining 185 cases (median age: 66 years, range: 43–84 years), both questionnaire information and blood samples were available. Most of the HCC cases (78.2%) were histologically or cytologically confirmed; for the remaining cases, cancer diagnosis was based on ultrasound, tomography and elevated α -fetoprotein levels.

Controls were patients younger than 85 years admitted to the same hospitals for a wide spectrum of acute, non-neoplastic conditions. Patients whose hospital admission was due to diseases related to alcohol and tobacco, liver diseases (e.g., hepatitis, cirrhosis, and oesophageal varices) or other chronic diseases, which may have substantially modified their lifestyle, were excluded from the comparison group. Overall, 467 controls were contacted and 462 accepted to participate. Blood samples were available from 431 controls, and 404 provided information on body size (median age: 65 years, range: 40–82 years). Twenty-six per cent of controls were admitted for traumas, 25% for acute surgical conditions, 24% for nontraumatic orthopaedic diseases, 14% for eye diseases, and 10% for other illnesses.

Each case and control provided a 15-ml blood sample the same day of the interview. Sera were screened for antibodies against HCV (anti-HCV) using a third-generation MEIA (AxSYM HCV version 3.0; Abbott Diagnostic Division, Wiesbaden, Germany) and for Hepatitis B surface antigen (HBsAg) using microparticle enzyme immunoassay (AxSYM HBsAg version 2.0; Abbott Diagnostic Division). All study participants signed an informed consent form, according to the recommendations of the Board of Ethics of the National Cancer Institute of Aviano.

Cases and controls were interviewed during their hospital stay using a structured questionnaire including information on socio-demographic characteristics, lifestyle habits (e.g., tobacco smoking and alcohol drinking), usual diet, personal medical history, and family history of cancer. Self-reported information on height and weight at different ages was collected, and body mass index (BMI) was computed according to Quetelet's index (weight/height^2 , kg m^{-2}). As information on waist circumference was not available, abdominal obesity was defined using BMI, according to two different thresholds, that is, ≥ 25 and $\geq 30 \text{ kg m}^{-2}$. History of medical conditions, including type-2 diabetes, drug-treated hypertension, and drug-treated or clinical diagnosis of hypercholesterolaemia was self-reported, and included age at first diagnosis. Diseases whose onset was < 1 year before hospital admission were not considered.

The indicator of MetS was defined according to the criteria agreed in the 2009 joint interim statement (Alberti *et al*, 2009), adapted to our data, as the presence of at least three components among the following: (1) abdominal obesity, (2) history of a clinical diagnosis or drug-treated hypercholesterolaemia (as a proxy indicator of increased low-density lipoprotein/reduced HDL cholesterol levels), (3) history of drug-treated hypertension (as an alternate indicator of elevated blood pressure), and (4) history of diabetes. We also considered various components of the MetS separately.

Data analysis. Odds ratios (ORs) of HCC, and the corresponding 95% confidence intervals (CIs), for MetS, its components or various combination of components, were derived using unconditional multiple logistic regression models, including terms for centre, sex, age (< 55 , 55–64, 65–74, ≥ 75 years), education (< 7 , 7–11, ≥ 12 years), alcohol drinking status (never, ex, current), and maximum lifetime alcohol intake (< 21 , ≥ 21 drinks per week), smoking habits (never, ex, current: < 15 cigarettes per day, current: ≥ 15 cigarettes per day), HBsAg and/or anti-HCV positivity, and non-alcohol energy intake.

RESULTS

Table 1 shows the distribution of 185 cases of HCC and 404 controls according to centre, age, sex, and other covariates. Controls were more often females and were younger than cases. Cases were more likely than controls to have a low level of education, to smoke cigarettes, and to report heavy alcohol drinking; 147 cases (79%) and 44 controls (11%) had serological evidence of chronic infection with HBV and/or HCV.

Table 2 reports the ORs of HCC according to separate and combined components of the MetS. The OR for diabetes was 4.33 (95% CI, 1.89–9.86); no association emerged with treated hypertension and hypercholesterolaemia. The ORs were 1.25 (95% CI, 0.72–2.18) for BMI $\geq 25 \text{ kg m}^{-2}$ and 1.97 (95% CI, 1.03–3.79) for BMI $\geq 30 \text{ kg m}^{-2}$. When obesity was defined as BMI $\geq 25 \text{ kg m}^{-2}$, as compared with subjects without any MetS component, the OR was 0.90 (95% CI, 0.47–1.74) for those with one MetS component, and 1.74 (95% CI, 0.82–3.69) for those with ≥ 2 components (P for trend = 0.149). The OR for the indicator of MetS was 4.06 (95% CI, 1.33–12.38). When obesity was defined as BMI $\geq 30 \text{ kg m}^{-2}$, the ORs were 1.18 (95% CI, 0.64–2.15) and 3.46 (95% CI, 1.54–7.73) for those with one and ≥ 2 MetS components, respectively (P for trend = 0.009). The OR for the presence of the MetS indicator was 1.92 (95% CI, 0.38–9.76).

Table 3 reports results for diabetes and obesity (the only two MetS components associated to HCC risk in our data set), and number of MetS components according to serological evidence of chronic infection with HBV and/or HCV, and in a subset of subjects (11 cases and 216 controls) without markers of chronic

Table 1. Distribution of 185 cases of hepatocellular carcinoma and 404 controls according to selected variables. Italy, 1999–2002

	Cases		Controls	
	N	%	N	%
Centre				
Aviano/Pordenone	61	33	224	55
Naples	124	67	180	45
Sex				
Males	149	81	278	69
Females	36	19	126	31
Age (years)				
<55	18	10	83	20
55–64	56	30	115	29
65–74	84	45	144	36
≥75	27	15	62	15
Education (years)				
<7	126	68	225	56
7–11	45	24	93	23
≥12	14	8	86	21
Smoking habits				
Never	50	27	134	33
Former	67	36	165	41
Current, cigarettes per day				
1–14	35	19	54	13
≥15	33	18	51	13
Drinking habits				
Abstainer	16	9	62	15
Current	75	40	302	75
Former	94	51	40	10
Maximal lifetime alcohol intake^a (drinks per week)				
<21	64	35	186	46
≥21	105	57	156	39
Non-alcohol energy intake (quartiles^b)				
I	28	15	101	25
II	39	21	101	25
III	51	28	101	25
IV	67	36	101	25
Hepatitis viruses^c				
No	38	21	360	89
Yes	147	79	44	11

^aCurrent and former drinkers combined.^bQuartiles were based on the distribution of non-alcohol energy intake among controls only.^cHepatitis was defined as HBsAg and/or anti-HCV positivity.

infection with HBV and/or HCV and with a lifetime alcohol intake <21 drinks per week. Results are given for obesity defined as BMI $\geq 30 \text{ kg m}^{-2}$. Diabetes showed an about three-fold increase in risk of HCC in subjects with and without chronic hepatitis, although the association was significant in the HBsAg– and anti-HCV– group only; obesity and the number of MetS components were

associated to HCC in hepatitis-free subjects only, in particular, in those with moderate alcohol consumption.

The combined effect of overweight (i.e., BMI $\geq 25 \text{ kg m}^{-2}$) and diabetes on HCC risk is shown in Figure 1. Compared with the lowest risk category, that is normal-weight subjects without diabetes, the ORs were 1.13 (95% CI, 0.63–2.06) for overweight subjects without diabetes, 4.38 (95% CI, 0.84–22.88) for diabetics of normal weight, and 4.75 (95% CI, 1.75–12.89) for those with both conditions.

DISCUSSION

In this Italian data set, the risk of HCC increased with the number of MetS components, up to an almost four-fold excess risk among subjects with ≥ 2 MetS factors, and to over six-fold in subjects without markers of chronic infection with HBV and/or HCV. There was no consistent association in subjects HBsAg+ or anti-HCV+. Metabolic syndrome is a general definition including several factors linked to overweight and hyperinsulinemia. Of these, only diabetes and overweight/obesity were associated to HCC risk in this study, although the relation with BMI was influenced by the threshold chosen. However, inference on hypercholesterolaemia was limited by the availability of information on treated subjects only, who were infrequent in Italy at the time of data collection, and data on hypertension were related to drug-treated hypertension only.

Our results are in broad agreement with previous data on the issue, which showed a positive association of MetS with liver cancer (Russo *et al*, 2008; Inoue *et al*, 2009; Borena *et al*, 2011; Welzel *et al*, 2011). When the single MetS components were analysed separately, overweight/obesity and high blood glucose revealed the strongest associations with liver cancer (Inoue *et al*, 2009; Borena *et al*, 2011).

Of specific interest, we found an association between the number of MetS components and HCC risk only among subjects without markers of chronic infection with HBV and/or HCV. In the Japan Public Health center-based prospective Study Cohort II, MetS increased the risk of HCC also among subjects with HCV infection (Inoue *et al*, 2009). In that study, among the single metabolic factors, only overweight was, however, positively associated to HCC risk in anti-HCV+ subjects. A 14 years follow-up study in Taiwan recruiting 23 820 subjects, for a total of 291 HCC cases, found that obesity (i.e., BMI $\geq 30 \text{ kg m}^{-2}$) and central obesity (i.e., waist circumference > 90 in men and > 80 in women) were independently associated with a two-fold and a four-fold increased HCC risk among HCV-seropositive subjects, respectively (Chen *et al*, 2008). In the same study, diabetes was associated with a two- to three-fold increased HCC risk, regardless of the presence of chronic infection with hepatitis viruses. However, the risk was highest in HBsAg– and anti-HCV+ subjects (Chen *et al*, 2008).

Diabetes and obesity have been previously related to HCC risk. This study considers the role of their combined effect in the MetS, and their interaction, as well as the modifying effect of HBV and/or HCV on the relation between MetS and liver cancer risk. Diabetes, in fact, has been associated with an about two-fold increased risk of HCC (La Vecchia *et al*, 1994; Adami *et al*, 1996; La Vecchia *et al*, 1997; Wideroff *et al*, 1997; Lagiou *et al*, 2000; El-Serag *et al*, 2004; Yuan *et al*, 2004; Lai *et al*, 2006; Polesel *et al*, 2009; La Vecchia, 2011; Bosetti *et al*, 2012), and precedes the development of both cirrhosis and HCC (Tanaka *et al*, 1997; Dellon and Shaheen, 2005; London and McGlynn, 2006). Insulin resistance has been related to the accumulation of liver fat and to excess cancer risk through the insulin-related growth factors (La Vecchia *et al*, 2011).

Table 2. Distribution of 185 cases of hepatocellular carcinoma and 404 controls, OR and corresponding 95% CI^a, according to separate, combined components and indicators of MetS. Italy, 1999–2002

	All subjects				OR (95% CI) ^a
	Cases		Controls		
	<i>n</i>	%	<i>n</i>	%	
Separate components					
Diabetes					
No	148	80	378	94	Ref
Yes	37	20	26	6	4.33 (1.89–9.86)
Treated hypertension					
No	144	78	288	71	Ref
Yes	41	22	116	29	1.13 (0.61–2.09)
Treated hypercholesterolaemia					
No	183	99	380	94	Ref
Yes	2	1	24	6	0.39 (0.05–2.85)
Obesity					
BMI ≥ 25 kg m ^{−2}					
No	71	38	146	36	Ref
Yes	114	62	258	64	1.25 (0.72–2.18)
BMI ≥ 30 kg m ^{−2}					
No	147	80	323	80	Ref
Yes	38	20	81	20	1.97 (1.03–3.79)
Combined components					
Number of MetS components					
(a) Obesity: BMI ≥ 25 kg m ^{−2}					
None	53	29	105	26	Ref
1	80	43	190	47	0.90 (0.47–1.74)
≥ 2	52	28	109	27	1.74 (0.82–3.69)
<i>P</i> for trend = 0.149					
Increment of 1 MetS component					1.39 (0.99–1.95)
(b) Obesity: BMI ≥ 30 kg m ^{−2}					
None	97	52	219	54	Ref
1	62	34	133	33	1.18 (0.64–2.15)
≥ 2	26	14	52	13	3.46 (1.54–7.73)
<i>P</i> for trend = 0.009					
Increment of 1 MetS component					1.58 (1.12–2.23)
Indicator of MetS ^b					
(a) Obesity: BMI ≥ 25 kg m ^{−2}					
No	175	95	388	96	Ref
Yes	10	5	16	4	4.06 (1.33–12.38)
(b) Obesity: BMI ≥ 30 kg m ^{−2}					
No	181	98	394	98	Ref
Yes	4	2	10	2	1.92 (0.38–9.76)

Abbreviations: BMI = body mass index; CI = confidence interval; MetS = metabolic syndrome; OR = odds ratio.

^aEstimated from unconditional logistic regression model adjusted for centre, sex, age, education, drinking status, maximum lifetime alcohol intake, smoking habits, HBsAg and/or anti-HCV positivity, and non-alcohol energy intake.

^bAt least three of the separate components.

With reference to obesity, a meta-analysis, including >6000 cases from 10 cohort studies, showed an 89% excess HCC risk among obese (i.e. BMI, ≥ 30 kg m⁻²) compared with subjects of normal weight; the pooled relative risk associated to overweight (BMI ranging from 25 to 30 kg m⁻²) was 1.17 (95% CI, 1.02–1.34).

The excess risk of liver cancer associated with overweight/obesity and diabetes has been related to the development of non-alcoholic fatty liver disease (NAFLD) (Sanyal *et al*, 2010). NAFLD is characterised by excess fat accumulation in the liver, and ranges

from isolated hepatic steatosis to non-alcoholic steatohepatitis (NASH), the more aggressive form of fatty liver disease, which can progress to cirrhosis and HCC (Neuschwander-Tetri and Caldwell, 2003; Larsson and Wolk, 2007; Siegel and Zhu, 2009; Montella *et al*, 2011a). However, NAFLD/NASH increases HCC risk even in the absence of cirrhosis (Ertle *et al*, 2011). Adipose tissue secretes a variety of bioactive hormones, collectively referred to as adipokines, which produce vascular endothelial growth factor, which may contribute to tumour progression (Rega *et al*, 2007). Excess

Table 3. Distribution of 185 hepatocellular carcinoma cases and 404 controls, OR^a and corresponding 95% CI, according to diabetes and obesity, and number of MetS components, by serological evidence of chronic infection with hepatitis B and/or hepatitis C viruses. Italy, 1999–2002

	HBsAg – and anti-HCV –		HBsAg – and anti-HCV – and lifetime alcohol intake <21 drinks per week		HBsAg + or anti-HCV +	
	Ca:Co	OR (95% CI) ^a	Ca:Co	OR (95% CI) ^a	Ca:Co	OR (95% CI) ^a
Diabetes						
No	29:337	Ref	8:203	Ref	119:41	Ref
Yes	9:23	3.65 (1.37–9.75)	3:13	9.14 (1.39–60.29)	28:3	2.57 (0.61–10.64)
Obesity ^b						
No	22:288	Ref	7:170	Ref	125:35	Ref
Yes	16:72	3.32 (1.51–7.32)	4:46	2.69 (0.61–11.90)	22:9	0.69 (0.21–2.27)
Number of MetS components						
0	12:197	Ref	2:112	Ref	85:22	Ref
1	12:116	1.76 (0.70–4.45)	5:74	7.40 (0.90–61.10)	50:17	0.90 (0.35–2.31)
≥2	14:47	6.45 (2.35–17.75)	4:30	20.21 (1.96–208.49)	12:5	0.69 (0.15–2.99)
P for trend	<0.001		0.009		0.612	
Increment of 1 MetS component	2.16 (1.38–3.39)		3.41 (1.31–8.89)		0.84 (0.46–1.52)	

Abbreviations: Ca = cases; CI = confidence interval; Co = controls; HCV = hepatitis C virus; HBsAg = hepatitis B surface antigen; MetS = metabolic syndrome; OR = odds ratio.
^aEstimated from unconditional logistic regression model adjusted for centre, sex, age, education, drinking status (when appropriate), maximum lifetime alcohol intake (when appropriate), smoking habits, and non-alcohol energy intake.
^bObesity was defined as body mass index (BMI) ≥30 kg m^{−2}.

Figure 1. Distribution of 185 hepatocellular carcinoma cases and 404 controls, odds ratios (OR) and 95% confidence intervals (CIs) according to the combination of diabetes and overweight. Italy, 1999–2002. ORs were estimated from unconditional logistic regression model adjusted for centre, sex, age, education, drinking status, maximum lifetime alcohol intake, smoking habits, HBsAg and/or anti-HCV positivity, and non-alcohol energy intake. Overweight was defined as BMI ≥25 kg m^{−2}.

intracellular fatty acids, adenosine triphosphate depletion, oxidant stress, and mitochondrial dysfunction may cause hepatocellular injuries in the steatotic liver (Neuschwander-Tetri and Caldwell, 2003).

To limit possible sources of bias, we included in the control group subjects admitted for a wide spectrum of acute, non-neoplastic conditions, unrelated to the major risk factors for HCC. The practically complete participation rate and the comparable catchment areas of cases and controls contributed to reduce any potential selection bias. Cases may recall history of disease more frequently than controls. However, the hospital setting should have improved the comparability of information, as cases and controls are interviewed under similar conditions (Breslow and Day, 1980).

Among limitations, information on MetS components was based on self-reported data from a questionnaire, which collected history of diabetes, treated hypertension, and treated hyperlipidaemia, rather than direct measurements of fasting plasma glucose, blood pressure, triglycerides and HDL cholesterol. Underestimation of the prevalence of MetS may therefore have occurred. However, data on diabetes collected on our questionnaire were satisfactorily reliable, with a kappa statistic of 0.85 from almost 300 subjects interviewed twice (Bosetti *et al*, 2001). Moreover, a recent cohort study from Spain showed that self-declared data on the criteria of MetS and on MetS itself are sufficiently accurate for epidemiological inference (Barrio-Lopez *et al*, 2011). Validation studies of hypertension confirmed with a medical examination found a reasonable accuracy of self-reported information; a somewhat lower validity was usually found for self-reported hypercholesterolaemia (Colditz *et al*, 1986; Giles *et al*, 1995; Vargas *et al*, 1997; Martin *et al*, 2000). Weight also was self-reported and possibly underestimated, particularly in overweight and obese subjects (Stark *et al*, 1981; Stewart, 1982; Millar, 1986). However, such information bias is likely to be similar for cases and controls, and, consequently, should have led to an attenuation of the real association (Breslow and Day, 1980). In addition, information on presence of fatty liver/NAFLD/NASH was not available in our study.

Another possible limitation is the use of BMI as a proxy of waist circumference in defining people with central obesity. However, the World Health Organization, in its formulation of MetS diagnostic criteria, considered BMI as a valid proxy of waist-to-hip ratio (Alberti *et al*, 2006). In our analyses, abdominal obesity was defined as either BMI ≥25 or BMI ≥30 kg m^{−2}, and the excess risk associated to the MetS persisted even when the lower threshold was considered. We used one of the possible MetS definition proposed in the literature (Alberti *et al*, 2009). When the presence of MetS was defined according to the International Diabetes Federation criteria (Third Report of the NCEP Expert Panel, 2002) (adapted to our data) as the presence of central obesity plus at least two other components, the OR for the

indicator of MetS did not substantially change (OR = 2.12, 95% CI, 0.40–11.26, with obesity defined as BMI ≥ 30 kg m⁻²; OR = 4.36, 95% CI, 1.40–13.56, with obesity defined as BMI ≥ 25 kg m⁻²).

The different prevalence of chronic hepatitis infection with HBV/HCV between HCC cases and controls, and the relatively low prevalence of obesity (i.e., BMI ≥ 30 kg m⁻²) and other MetS components in our study sample, limited our results on these associations, particularly in subgroup analyses. In light of these considerations, caution in interpreting these results is needed.

Concerning confounding, the associations persisted after adjustment for the main recognised HCC risk factors, including chronic infection with HBV/HCV, tobacco smoking, and alcohol drinking.

ACKNOWLEDGEMENTS

This work was conducted with the contribution of the Italian Association for Cancer Research (AIRC) (grant number: 10068), the Flight Attendants Medical Research Institute Center of Excellence (Award 052460_CoE), and the Italian League Against Cancer (LILT) (project number:11/2008). We thank Mrs I Garimoldi for her editorial assistance.

REFERENCES

- Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekblom A, Wolk A, McLaughlin JK, Fraumeni Jr JF (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. *J Natl Cancer Inst* **88**: 1472–1477.
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman Jr, Donato KA, Fruchart JC, James WP, Loria CM, Smith Jr SC (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **120**: 1640–1645.
- Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. *Lancet* **366**: 1059–1062.
- Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* **23**: 469–480.
- Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* **15**: 539–553.
- Barrio-Lopez MT, Bes-Rastrollo M, Beunza JJ, Fernandez-Montero A, Garcia-Lopez M, Martinez-Gonzalez MA (2011) Validation of metabolic syndrome using medical records in the SUN cohort. *BMC Public Health* **11**: 867.
- Borena W, Strohmaier S, Lukanova A, Bjorge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Haggstrom C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H (2011) Metabolic risk factors and primary liver cancer in a prospective study of 578 700 adults. *Int J Cancer* **131**(1): 193–200.
- Bosetti C, Rosato V, Polesel J, Levi F, Talamini R, Montella M, Negri E, Tavani A, Zucchetto A, Franceschi S, Corrao G, La Vecchia C (2012) Diabetes mellitus and cancer risk in a network of case-control studies. *Nutr Cancer* **64**: 643–651.
- Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C (2001) Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. *J Clin Epidemiol* **54**: 902–906.
- Breslow NE, Day NE (1980) *Statistical methods in cancer research. Vol. I. The analysis of case-control studies*. IARC: Lyon, France.
- Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. *Gastroenterology* **135**: 111–121.
- Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. *Am J Epidemiol* **123**: 894–900.
- Dellon ES, Shaheen NJ (2005) Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. *Gastroenterology* **129**: 1132–1134.
- El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* **126**: 460–468.
- Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* **128**: 2436–2443.
- Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, Casarin P, Izzo F, Tommasi LG, Chemin I, Trepo C, Crovatto M, Talamini R (2006) Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. *Cancer Epidemiol Biomarkers Prev* **15**: 683–689.
- Giles WH, Croft JB, Keenan NL, Lane MJ, Wheeler FC (1995) The validity of self-reported hypertension and correlates of hypertension awareness among blacks and whites within the stroke belt. *Am J Prev Med* **11**: 163–169.
- Grundy SM, Cleeman Jr, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* **112**: 2735–2752.
- Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S (2009) Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). *Cancer Causes Control* **20**: 741–750.
- La Vecchia C (2011) Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. *Metabolism* **60**: 1357–1358.
- La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011) Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. *Oncologist* **16**: 726–729.
- La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and the risk of primary liver cancer. *Int J Cancer* **73**: 204–207.
- La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P (1994) A case-control study of diabetes mellitus and cancer risk. *Br J Cancer* **70**: 950–953.
- Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO (2000) Role of diabetes mellitus in the etiology of hepatocellular carcinoma. *J Natl Cancer Inst* **92**: 1096–1099.
- Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. *Hepatology* **43**: 1295–1302.
- Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. *Br J Cancer* **97**: 1005–1008.
- Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. *Lancet* **362**: 1907–1917.
- London WT, McGlynn KA (2006) Liver cancer. In *Cancer Epidemiology and Prevention*, Schottenfeld D, Fraumeni Jr JF (eds) 3rd edn pp 763–786. Oxford University Press: New York.
- Martin LM, Leff M, Calonge N, Garrett C, Nelson DE (2000) Validation of self-reported chronic conditions and health services in a managed care population. *Am J Prev Med* **18**: 215–218.
- Millar WJ (1986) Distribution of body weight and height: comparison of estimates based on self-reported and observed measures. *J Epidemiol Community Health* **40**: 319–323.
- Montella M, Crispo A, Giudice A (2011a) HCC, diet and metabolic factors: Diet and HCC. *Hepat Mon* **11**: 159–162.
- Montella M, Polesel J, Talamini R, Crispo A, Giudice A, Izzo F, La Vecchia C (2011b) Metabolic syndrome is also a risk factor for primary liver cancer in patients younger than 65 years of age? *Hepatology* **54**: 2277–2278.
- Mueller NE, Birmann BM, Parsonnet J, Schiffman MH, Stuver S (2006) Infectious agents. In *Cancer Epidemiology and Prevention*, Schottenfeld D, Fraumeni Jr JF (eds) 3rd edn pp 507–548. Oxford University Press: New York.
- Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* **37**: 1202–1219.
- Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R (2009) The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. *Ann Oncol* **20**: 353–357.

- Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K, Wojta J (2007) Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue *in vitro* and in murine adipose tissue *in vivo*. *Arterioscler Thromb Vasc Biol* **27**: 1587–1595.
- Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. *Eur J Cancer* **44**: 293–297.
- Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. *Oncologist* **15**(Suppl 4): 14–22.
- Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. *Cancer* **115**: 5651–5661.
- Stark O, Atkins E, Wolff OH, Douglas JW (1981) Longitudinal study of obesity in the National Survey of Health and Development. *Br Med J* **283**: 13–17.
- Stewart AL (1982) The reliability and validity of self-reported weight and height. *J Chronic Dis* **35**: 295–309.
- Stuver S, Trichopoulos D (2008) Cancer of the liver and biliary tract. In *Cancer Epidemiology*, Adami H-O, Hunter D, Trichopoulos D (eds) 2nd edn pp 308–332. Oxford University Press: New York.
- Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, Spina M, Pinto A, Carbone A, Franceschi S (2004) Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. *Int J Cancer* **110**: 380–385.
- Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR (1997) Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. *Hepatology* **26**: 598–604.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002) *Circulation* **106**: 3143–3421.
- Vargas CM, Burt VL, Gillum RF, Pamuk ER (1997) Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988–1991. *Prev Med* **26**: 678–685.
- Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology* **54**: 463–471.
- Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* **89**: 1360–1365.
- Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. *Cancer* **101**: 1009–1017.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.